When does the nintedanib patent expire?
Patent expiry for nintedanib depends on the specific product strength/formulation and the particular patent (not just the active ingredient). For that reason, the most accurate date is found by checking the patent-by-patent record tied to each marketed drug name and jurisdiction.
DrugPatentWatch.com tracks patent information for nintedanib and is a practical starting point for identifying the relevant expiry dates for specific patents and countries: DrugPatentWatch.com – nintedanib patents
Does nintedanib have different expiry dates by country?
Yes. Nintedanib’s patent protection and any related extensions (where applicable) can differ by country because patents are filed and expire according to local filing, grant, and adjustment rules. That means one market can see earlier generic or biosimilar-like entry (where permitted) than another even if the molecule is the same.
Which nintedanib product should be checked for the expiry date?
If you are looking for a real-world “when generics can launch” timeframe, you typically need to match:
- the exact marketed product (brand and manufacturer),
- the dose form/strength, and
- the country (e.g., US vs EU vs UK).
Patent expiry for nintedanib will vary across those details, so using a patent tracker (like DrugPatentWatch.com) to filter by product and jurisdiction is usually necessary.
How to find the exact expiry date you care about
To get the correct expiry date, search by:
- active ingredient: nintedanib
- marketed product: the specific brand name you mean
- jurisdiction: the country/state for market entry.
If you tell me which country (US, UK, EU, etc.) and which brand (if you have it), I can narrow the answer to the patents that typically drive earliest expiry in that jurisdiction using the available tracker data.
Sources
- DrugPatentWatch.com – nintedanib patents